125 results on '"Ragde H"'
Search Results
2. Safety and efficacy of dendritic cell (DC)-based cryoimmunotherapy (CryoIT) combined with checkpoint inhibition in a prospective non-randomized Phase I trial of metastatic castration resistant prostate cancer (mCRPC)
3. Treatment of Prostate Cancer Patients with a Combination of Cryoablation and Intratumoral Injection of Autologous Dendritic Cells: ABS/PP-02/ACUBali/06-O
4. CYTOTOXIC TYPING ANTISERA FOR MARROW GRAFTING IN LITTERMATE DOGS
5. Treatment of localized disease
6. OPTIMIZATION OF CANNULAS FOR MAINTENANCE HEMODIALYSIS
7. Current prognostic factors and their relevance to staging.
8. Modern prostate brachytherapy
9. Follow-up evaluation of a phase II prostate cancer vaccine trial
10. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial
11. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
12. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
13. Ten-Year Disease Free Survival After Transperineal Sonography-Guided Iodine-125 Brachytherapy With or Without 45-Gray External Beam Irradiation in the Treatment of Patients With Clinically Localized, Low to High Gleason Grade Prostate Carcinoma
14. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
15. Dendritic Cell-Based Immunotherapy of Prostate Cancer
16. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
17. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
18. Prostate brachytherapy: importance of technique.
19. Measurement of prostate-specific membrane antigen in the serum with a new antibody
20. Brachytherapy for prostate cancer
21. Hemophilia role of organ homografts
22. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma.
23. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma.
24. MARROW GRAFTS BY COMBINED MARROW AND LEUKOCYTE INFUSIONS IN UNRELATED DOGS SELECTED BY HISTOCOMPATIBILITY TYPING.
25. CYTOTOXIC TYPING ANTISERA FOR MARROW GRAFTING IN LITTERMATE DOGS.
26. Posttreatment Biopsy Results Following Interstitial Brachytherapy in Early-Stage Prostate Cancer
27. Measurement of Serum Prostate-Specific Membrane Antigen, a New Prognostic Marker for Prostate Cancer
28. Reduction of Radioactive Seed Embolization to the Lung Following Prostate Brachytherapy
29. Marrow Engraftment by Allogeneic Leukocytes in Lethally Irradiated Dogs
30. Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs
31. Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs
32. Hemophilia: Role of Organ Homografts
33. Hemophilia: role of organ homografts
34. "Functioning" Pulmonary Neoplasms: I. The Carcinoid Tumor; II. The Hemangiopericytoma
35. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
36. 13 Prostate brachytherapy
37. A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer.
38. Chemotherapy followed by syngeneic dendritic cell injection in the mouse: findings and implications for human treatment.
39. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006.
40. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer.
41. Radiotherapy for prostate cancer: brachytherapy alone.
42. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up.
43. Adjuvant chemohormonal therapy of high risk prostate carcinoma. Ten year results.
44. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.
45. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
46. Brachytherapy for clinically localized prostate cancer.
47. Method for identifying prostate cells in semen using flow cytometry.
48. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).
49. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
50. Prostate cancer brachytherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.